I’m Nunny Keyla Reece. I was Diagnosed in 2017 ER/PR + HER2-Metastatic Breast Cancer.
My first mammogram was 9/18/15 after feeling a lump in my right breast. The radiologist told me it was benign fatty tissue and to come back in six months for a checkup or sooner if I noticed any changes. Of course, I didn’t go back in six months because there were no changes, no history of breast cancer in my family, and I was only 37 years old at the time. Around the end of May in 2017 I found a new lump up under my arm and around the same time I started having this severe pain in my back. I tried to ignore it because a lot was happening in my life at the moment. My mom had just passed away from Alzheimers and about five weeks after her death my dad passed away from stage IV colon cancer. Going to the doctor wasn’t on the top of my list until I woke up one morning and couldn’t get out of bed because of the severe back pain. Eventually I went to the doctor. On June 7,2017 I had a mammogram and ultrasound, and it came back highly suspicious for malignancy at the age of 39. On June 12, 2017, I had a breast biopsy which confirmed the breast cancer. Additional images and tests confirmed that I was already a metastatic breast cancer patient. That was a hard pill to swallow. All I could think about was my husband and children.
I started to attend conferences to educate myself. I started sharing my story to educate my community as well. When I was diagnosed I felt alone. I did not see other African American women like myself. But it became deeper than that. To hear other AA women say they knew nothing about MBC was unacceptable. AA women would also say because they didn’t see us on TV commercials,magazines,conferences,brochures they thought it was only a white woman disease. That too was unacceptable.
In 2018 I became Young Advocate for Living Beyond Breast Cancer, 2019 I became an Advocate for the
Susan G. Komen North Carolina Triangle and 2020 I joined the Tigerlily Foundation as a Angel Advocate. I work hard in community sharing information regarding MBC.
Craig H. Lipset is Head of Clinical Innovation within Worldwide Research & Development at Pfizer. Craig’s team is responsible for impacting clinical research through digital tools, innovative research approaches and unprecedented collaborations. He serves on the Board of Directors for the Foundation for Sarcoidosis Research, the Board of Directors for the MedStar Health Research Institute, the Operations Committee for TransCelerate BioPharma, and as a Mentor at health tech accelerator Blueprint Health. Craig also serves on the Editorial Board for Therapeutic Innovation & Regulatory Science.
Craig previously served as Venture Partner in Pfizer Venture Investments as well as Senior Director in Molecular Medicine within Pfizer R&D. Prior to Pfizer he served as Associate Vice President of Program Management at Adnexus Therapeutics (acquired by Bristol-Myers Squibb), and on the founding management team for Perceptive Informatics (now part of PAREXEL International).
Craig’s areas of expertise include patient engagement, applications of digital platforms for clinical research, innovation and change management. His team currently manages Pfizer’s initiatives, investments, and collaborations to re-invent clinical research. In recent years, Craig has been listed among the 2010 PharmaVOICE most inspiring people in the life sciences, featured in Pharmaceutical Executive’s 2011 Emerging Leaders, and his work acknowledged with the 2012 BioIT Best Practices award for Clinical & Health IT.
For twenty years, I have used big data to answer scientific and business questions. I hold a Ph.D. in neuroscience and have also worked in fields including genomics, web analytics, and user interaction. I start by working with stakeholders or scientific colleagues to determine most actionable questions and reviewing existing data and research. This includes assessing what can reasonably be answered based on existing data or ongoing experiments. If further data collection is required, I design experiments and data collection systems to answer the determined questions. I have worked with a variety of data analysis methods from basic statistics to statistical models and machine learning, and learn new methods as necessary.
I currently work as a consultant for companies and academic groups with data science needs.